NCT05826717

Brief Summary

Epidemiological evidence is accumulating that a high consumption of added sugars is associated with metabolic diseases such as non-alcoholic fatty liver disease and type 2 diabetes. Fructose, one of the principal added sugars, is believed to be the most disadvantageous sugar. Data from a large population-based cohort demonstrated that fructose intake from fruit juice and sugar-sweetened beverages, but not whole fruits, is associated with higher intrahepatic lipid content. A study in mice demonstrated that fast fructose exposure resulted in higher intrahepatic lipid content than slow fructose exposure. The food matrix, i.e. the complex spatial organisation of and interactions between nutrients, may account for the fast versus slow fructose exposure and subsequent health consequences. Therefore the investigators aim to investigate the role of the fructose matrices on serum fructose peaks. The investigators hypothesize that liquid fructose matrices will cause higher serum fructose peaks in comparison to solid fructose matrices. Objective: To quantify serum fructose peaks within 150 minutes following intake of fructose-containing matrices.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
23

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Dec 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 15, 2022

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 28, 2023

Completed
27 days until next milestone

First Posted

Study publicly available on registry

April 24, 2023

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 20, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 20, 2024

Completed
Last Updated

February 20, 2025

Status Verified

February 1, 2025

Enrollment Period

2 years

First QC Date

March 28, 2023

Last Update Submit

February 18, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in serum fructose between peak and baseline

    Time points 0, 15, 30, 45, 60, 75, 90, 105, 120, 135 and 150 minutes following consumption of the food product.

Secondary Outcomes (2)

  • Blood pressure

    Time points 0, 15, 30, 45, 60, 75, 90, 105, 120, 135 and 150 minutes following consumption of the food product.

  • Serum uric acid

    Time points 0, 15, 30, 45, 60, 75, 90, 105, 120, 135 and 150 minutes following consumption of the food product.

Study Arms (4)

Food product 1.

EXPERIMENTAL

\[x\] gr apple containing 20 gr fructose as measured with an enzymatic method. Administered one time.

Other: Apple

Food product 2.

EXPERIMENTAL

\[x\] gr mashed apple containing 20 gr fructose as measured with an enzymatic method. Administered one time.

Food product 3.

EXPERIMENTAL

\[x\] ml apple juice containing 20 gr fructose as measured with an enzymatic method. Administered one time.

Other: Apple juice

Food product 4.

EXPERIMENTAL

20 gr of fructose powder dissolved in 300 ml of water. Administered one time.

Other: Fructose powder in water

Interventions

AppleOTHER

20g fructose in \[x\] g of apple

Food product 1.

20g fructose in \[x\] g of mashed apple

20g fructose in \[x\] ml apple juice

Food product 3.

20g fructose in \[x\] ml water

Food product 4.

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 years.
  • Body mass index (BMI) ≥18.5 kg/m2 and \<25 kg/m2

You may not qualify if:

  • Pregnancy.
  • Drugs and/or alcohol abuse.
  • Diagnosis of diabetes mellitus.
  • (History of) gastrointestinal and/or liver disease.
  • (History \[\< 5 years\] of) cancer (excluding basal cell carcinoma)
  • Allergy to one of the used food products in the study.
  • Inability to provide written informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Academic Hospital Maastricht

Maastricht, 6229 HX, Netherlands

Location

MeSH Terms

Interventions

Water

Intervention Hierarchy (Ancestors)

HydroxidesAlkaliesInorganic ChemicalsAnionsIonsElectrolytesOxidesOxygen Compounds

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Model Details: This study is an open-label, randomized, single meal, cross-over study in healthy individuals.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 28, 2023

First Posted

April 24, 2023

Study Start

December 15, 2022

Primary Completion

December 20, 2024

Study Completion

December 20, 2024

Last Updated

February 20, 2025

Record last verified: 2025-02

Locations